Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05300438 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.
A Phase 1 study of Cancer (With or Without Metastasis), sponsored by Tyligand Bioscience (Shanghai) Limited.
- Active
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT05300438: Active Phase 1 study of Cancer (With or Without Metastasis), sponsored by Tyligand Bioscience (Shanghai) Limited.
NCT05300438 is a Phase 1 study of Cancer (With or Without Metastasis) that is active but no longer recruiting, run by Tyligand Bioscience (Shanghai) Limited. The registered enrollment target is 74 participants, below the 450-participant average among 3 other Cancer (With or Without Metastasis) trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05300438, a Phase 1 study of Cancer (With or Without Metastasis), is active but no longer recruiting, sponsored by Tyligand Bioscience (Shanghai) Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
TSN084 is a novel type II protein kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of TSN084 in advanced or metastatic malignancies.
Conditions Studied
Interventions
- DRUG TSN084
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2022-02-18 |
| Est. Completion | 2025-06 |
| Phase | Phase 1 |
What the registry record for NCT05300438 still lists
NCT05300438 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 450-participant average among 3 other Cancer (With or Without Metastasis) trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Cancer (With or Without Metastasis) appearing as the primary indexed condition, and to 1 intervention - of which TSN084 is the first listed.
NCT05300438 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05300438 about?
NCT05300438 is a clinical study titled "Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.". TSN084 is a novel type II protein kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose...
What is the current status of trial NCT05300438?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2022-02-18. Estimated completion is 2025-06.
What conditions does trial NCT05300438 study?
This clinical trial studies the following conditions: Cancer (With or Without Metastasis).
What interventions are being tested in trial NCT05300438?
The interventions under investigation include: TSN084 (DRUG).
Who is sponsoring clinical trial NCT05300438?
This trial is sponsored by Tyligand Bioscience (Shanghai) Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05300438 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer (With or Without Metastasis)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI